Current promising treatment strategy for glioblastoma multiform: A review
Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die wit...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-07-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://www.oncologyreviews.org/index.php/or/article/view/417 |
| _version_ | 1797964776876277760 |
|---|---|
| author | Sanjib Bahadur Arvind Kumar Sahu Pragya Baghel Suman Saha |
| author_facet | Sanjib Bahadur Arvind Kumar Sahu Pragya Baghel Suman Saha |
| author_sort | Sanjib Bahadur |
| collection | DOAJ |
| description | Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients. |
| first_indexed | 2024-04-11T01:49:15Z |
| format | Article |
| id | doaj.art-db44536c8ec54f0a9a68ee63d2dadd3c |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:49:15Z |
| publishDate | 2019-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-db44536c8ec54f0a9a68ee63d2dadd3c2023-01-03T07:01:14ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652019-07-0113210.4081/oncol.2019.417Current promising treatment strategy for glioblastoma multiform: A reviewSanjib Bahadur0Arvind Kumar Sahu1Pragya Baghel2Suman Saha3Department of Pharmaceutics, Columbia Institute of Pharmacy, Near Vidhan Sabha, Raipur, ChhattisgarhDepartment of Pharmaceutics, Columbia Institute of Pharmacy, Near Vidhan Sabha, Raipur, ChhattisgarhDepartment of Pharmaceutics, Columbia Institute of Pharmacy, Near Vidhan Sabha, Raipur, ChhattisgarhDepartment of Pharmaceutics, Columbia Institute of Pharmacy, Near Vidhan Sabha, Raipur, ChhattisgarhGlioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.https://www.oncologyreviews.org/index.php/or/article/view/417Glioblastomatemozolomideresistancetargeted therapy |
| spellingShingle | Sanjib Bahadur Arvind Kumar Sahu Pragya Baghel Suman Saha Current promising treatment strategy for glioblastoma multiform: A review Oncology Reviews Glioblastoma temozolomide resistance targeted therapy |
| title | Current promising treatment strategy for glioblastoma multiform: A review |
| title_full | Current promising treatment strategy for glioblastoma multiform: A review |
| title_fullStr | Current promising treatment strategy for glioblastoma multiform: A review |
| title_full_unstemmed | Current promising treatment strategy for glioblastoma multiform: A review |
| title_short | Current promising treatment strategy for glioblastoma multiform: A review |
| title_sort | current promising treatment strategy for glioblastoma multiform a review |
| topic | Glioblastoma temozolomide resistance targeted therapy |
| url | https://www.oncologyreviews.org/index.php/or/article/view/417 |
| work_keys_str_mv | AT sanjibbahadur currentpromisingtreatmentstrategyforglioblastomamultiformareview AT arvindkumarsahu currentpromisingtreatmentstrategyforglioblastomamultiformareview AT pragyabaghel currentpromisingtreatmentstrategyforglioblastomamultiformareview AT sumansaha currentpromisingtreatmentstrategyforglioblastomamultiformareview |